StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN – Free Report) in a research report report published on Wednesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright reissued a buy rating and set a $9.00 target price on shares of Trevena in a research report on Tuesday, April 2nd.
Check Out Our Latest Report on Trevena
Trevena Stock Down 3.2 %
Trevena (NASDAQ:TRVN – Get Free Report) last posted its earnings results on Monday, April 1st. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter. The firm had revenue of ($0.08) million during the quarter, compared to analyst estimates of $0.09 million. Research analysts anticipate that Trevena will post -1.28 EPS for the current fiscal year.
Institutional Trading of Trevena
An institutional investor recently bought a new position in Trevena stock. Armistice Capital LLC acquired a new position in shares of Trevena, Inc. (NASDAQ:TRVN – Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned about 4.61% of Trevena as of its most recent SEC filing. 13.56% of the stock is currently owned by hedge funds and other institutional investors.
About Trevena
Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.
Read More
- Five stocks we like better than Trevena
- How to Effectively Use the MarketBeat Ratings Screener
- Has FMC Stock Reached Bottom? First Quarter Earnings Say Yes
- Overbought Stocks Explained: Should You Trade Them?
- Lucid’s Stock Price is Still in Reverse: New Lows Are Coming
- Where Do I Find 52-Week Highs and Lows?
- Generac Powers Ahead on the Electrification Mega-Trend
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.